Baloxavir Protects Household Contacts From Influenza
Percentage of patients in whom clinical influenza developed significantly lower in baloxavir group.
Infectious Disease
Comparative Analysis Shows Remdesivir Cuts Death Risk in Severe COVID-19
Treatment with remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality in patients with severe coronavirus disease 2019.
FDA Fast-Tracks Two mRNA-Based COVID-19 Vaccine Candidates
The FDA has granted Fast Track designation to 2 of Pfizer and BioNTech’s vaccine candidates against COVID-19.
Risk for COVID-19 Increased for Adults Taking PPIs
Dose-response relationship observed; risk up 3.67-fold for those using PPIs up to twice daily.
2008 to 2018 Saw Increase in Shingles Vaccination in Over 60s
Women equally as likely as men to have received vaccine; coverage highest for non-poor, those with higher education.
MPR Weekly Dose Podcast Episode 42
This week we cover the discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.
NIH: New Network Aims to Enroll Thousands for COVID-19 Vaccine, Therapeutics Trials
The COVPN is part of “Operation Warp Speed”, a partnership led by the Department of Health and Human Services (HHS) to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
American Cancer Society Updates HPV Vaccination Guidelines
Vaccination should be routinely offered at age 9 to 12 years; catch-up vaccination recommended through age 26.
Mylan Recalls One Lot of Daptomycin for Injection
According to Mylan, the administration of the recalled product may lead to “serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.”
Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins
A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
